Press Releases

Press Releases

    Date Title View
    11/22/21
    Summary ToggleNew Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    11/15/21
    Summary ToggleHorizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
    PDF Version
    11/12/21
    Summary ToggleNew Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
    PDF Version
    11/12/21
    Summary ToggleHorizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    11/09/21
    Summary ToggleHorizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
    PDF Version
    11/08/21
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Conferences
    PDF Version
    11/05/21
    Summary ToggleHorizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
    PDF Version
    11/04/21
    Summary ToggleResults from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
    PDF Version
    11/03/21
    Summary ToggleHorizon Therapeutics plc Announces Chief Financial Officer Succession Plan
    PDF Version
    11/03/21
    Summary ToggleHorizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
    Displaying 1 - 10 of 619 results